Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This non-interventional descriptive study was undertaken to better understand the most common imaging features associated with inflammation arising in the post-marketing setting when brolucizumab was prescribed in routine clinical practice.
The purpose of this retrospective study analysis was to better characterize the risk of inflammatory events arising from use of brolucizumab in routine clinical practice through analysis of independently reviewed ocular imaging data obtained from cases with reports of intraocular inflammation (IOI), retinal vasculitis (RV) and/or Retinal vascular occlusion (RO) and to provide a description of these features.
Whenever an AE report pertaining to RV and/or RO was reported to Novartis Patient Safety, a follow-up check list (targeted follow-up checklists [TFUs]) was sent by Novartis to the reporter. The reporter was encouraged to share all available images obtained as part of clinical practice, irrespective of the timing or event (i.e. images before, during, and after event could be provided). The focus and main efforts of this data collection was on adverse events of RV and/or RO; for other IOI only events, the images were not actively requested in the case documentation process, however in some cases these were spontaneously reported by the reporter.
All images obtained from Feb 2020 up to 31 Jan 2021 were reviewed in a standardized manner by an external reading center. Dedicated grading lists were developed for each of the image modalities: Fluorescein Angiography (FA), Fundus Photography (FP), Indocyanine Green Angiography (ICGA), Optical Coherence Tomography (OCT), and OCT Angiography (OCT-A).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Brolucizumab | brolucizumab in routine clinical practice |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Brolucizumab | Other | Participants with cases of RV and/or RO reported to Novartis Patient Safety following brolucizumab use in routine clinical practice for which images were provided to Novartis and read by the Reading Centre were included |
| Measure | Description | Time Frame |
|---|---|---|
| Eye case classification based on imaging data | Eye case classification based on imaging data is provided:
| throughout the study period of 5 months |
| Number of eye cases by anatomical location and sub-location | Number of eye cases by anatomical location and sub-location is provided:
| throughout the study period of 5 months |
| Number of eye cases by occlusion type by reading center eye case classification | Occlusion type by reading center eye case classification is provided:
| throughout the study period of 5 months |
| Number of eye cases by Anatomical location in relation to macula | Number of eye cases by Anatomical location in relation to macula is provided: | throughout the study period of 5 months |
| Number of eye cases by extent of involvement of the retinal arterial and vein occlusion | Number of eye cases by Extent of involvement of the retinal arterial and vein occlusion is provided | throughout the study period of 5 months |
| Number of eye cases by grading variables per imaging modality by reading center eye case classification | Number of eye cases by grading variables per imaging modality by reading center eye case classification is provided |
Not provided
Not provided
Inclusion Criteria:
Not provided
Not provided
As this study used secondary data from Novartis Patient Safety database, there was no specified set of subject population in this study and all cases with event of interest and available images were retrieved.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis Investigative center | Basel | Switzerland |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| throughout the study period of 5 months |
| ID | Term |
|---|---|
| D014605 | Uveitis |
| D031300 | Retinal Vasculitis |
| ID | Term |
|---|---|
| D014603 | Uveal Diseases |
| D005128 | Eye Diseases |
| D012164 | Retinal Diseases |
| D014657 | Vasculitis |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000622091 | brolucizumab |
Not provided
Not provided
Not provided